{"id":"https://openalex.org/W2940825000","doi":"https://doi.org/10.1016/j.clinthera.2019.04.004","title":"A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies","display_name":"A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies","publication_year":2019,"publication_date":"2019-04-25","ids":{"openalex":"https://openalex.org/W2940825000","doi":"https://doi.org/10.1016/j.clinthera.2019.04.004","mag":"2940825000","pmid":"https://pubmed.ncbi.nlm.nih.gov/31030995"},"language":"en","primary_location":{"id":"doi:10.1016/j.clinthera.2019.04.004","doi":"https://doi.org/10.1016/j.clinthera.2019.04.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2019.04.004","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016570350","display_name":"David B. Huang","orcid":"https://orcid.org/0000-0001-8228-7911","observed_orcids":["https://orcid.org/0000-0001-8228-7911","https://orcid.org/0000-0002-8342-3193"]},"institutions":[{"id":"https://openalex.org/I4210140002","display_name":"Motif BioSciences (United States)","ror":"https://ror.org/04815fk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140002"]},{"id":"https://openalex.org/I4402554120","display_name":"Rutgers New Jersey Medical School","ror":"https://ror.org/014ye1258","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4402554120"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David B. Huang","raw_affiliation_strings":["Motif BioSciences, Princeton, NJ, USA; Rutgers New Jersey Medical School, Trenton, NJ, USA. Electronic address: david.huang@motifbio.com","Motif BioSciences, Princeton, NJ, USA","Rutgers New Jersey Medical School, Trenton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Motif BioSciences, Princeton, NJ, USA; Rutgers New Jersey Medical School, Trenton, NJ, USA. Electronic address: david.huang@motifbio.com","institution_ids":["https://openalex.org/I4402554120"]},{"raw_affiliation_string":"Motif BioSciences, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210140002"]},{"raw_affiliation_string":"Rutgers New Jersey Medical School, Trenton, NJ, USA","institution_ids":["https://openalex.org/I4402554120"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004741643","display_name":"Stephanie Noviello","orcid":"https://orcid.org/0000-0001-5555-9328","observed_orcids":["https://orcid.org/0000-0001-5555-9328"]},"institutions":[{"id":"https://openalex.org/I4210140002","display_name":"Motif BioSciences (United States)","ror":"https://ror.org/04815fk53","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140002"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie Noviello","raw_affiliation_strings":["Motif BioSciences, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Motif BioSciences, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210140002"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080852167","display_name":"Barbara Balser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267304","display_name":"Veristat, LLC (United States)","ror":"https://ror.org/023qnpq80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267304"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Balser","raw_affiliation_strings":["Veristat, Southborough, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Veristat, Southborough, MA, USA","institution_ids":["https://openalex.org/I4405267304"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074573989","display_name":"Amy Scaramucci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267304","display_name":"Veristat, LLC (United States)","ror":"https://ror.org/023qnpq80","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267304"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy Scaramucci","raw_affiliation_strings":["Veristat, Southborough, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Veristat, Southborough, MA, USA","institution_ids":["https://openalex.org/I4405267304"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5059959498","display_name":"G. Ralph Corey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Ralph Corey","raw_affiliation_strings":["Duke University Medical Center, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Durham, NC, USA","institution_ids":["https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5016570350"],"corresponding_institution_ids":["https://openalex.org/I4210140002","https://openalex.org/I4402554120"],"apc_list":{"value":3250,"currency":"USD","value_usd":3250},"apc_paid":null,"fwci":1.3138,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.78147384,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"41","issue":"6","first_page":"1090","last_page":"1096"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.7128999829292297,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10195","display_name":"Antimicrobial Resistance in Staphylococcus","score":0.7128999829292297,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.10329999774694443,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11153","display_name":"Streptococcal Infections and Treatments","score":0.05990000069141388,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iclaprim","display_name":"iclaprim","score":1.0},{"id":"https://openalex.org/keywords/vancomycin","display_name":"vancomycin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acute-bacterial-skin-and-skin-structure-infections","display_name":"acute bacterial skin and skin structure infections","score":0.9959999918937683},{"id":"https://openalex.org/keywords/injection-drug-use","display_name":"intravenous drug use","score":0.9049999713897705},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8360000252723694},{"id":"https://openalex.org/keywords/early-clinical-response","display_name":"early clinical response","score":0.968999981880188},{"id":"https://openalex.org/keywords/lesion-size-reduction","display_name":"lesion size reduction","score":0.9480000138282776},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8029999732971191},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5360000133514404},{"id":"https://openalex.org/keywords/antibiotic-efficacy","display_name":"antibiotic efficacy","score":0.3720000088214874}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9242537021636963},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6740913391113281},{"id":"https://openalex.org/C2778980435","wikidata":"https://www.wikidata.org/wiki/Q424027","display_name":"Vancomycin","level":4,"score":0.6687038540840149},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.540067195892334},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4910314083099365},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4763622283935547},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41338372230529785},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3343130648136139},{"id":"https://openalex.org/C2779489039","wikidata":"https://www.wikidata.org/wiki/Q188121","display_name":"Staphylococcus aureus","level":3,"score":0.11808547377586365},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014640","descriptor_name":"Vancomycin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015819","descriptor_name":"Substance Abuse, Intravenous","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017192","descriptor_name":"Skin Diseases, Bacterial","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D017192","descriptor_name":"Skin Diseases, Bacterial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D061605","descriptor_name":"Administration, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clinthera.2019.04.004","doi":"https://doi.org/10.1016/j.clinthera.2019.04.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.clinthera.2019.04.004","pdf_url":null,"source":{"id":"https://openalex.org/S185879095","display_name":"Clinical Therapeutics","issn_l":"0149-2918","issn":["0149-2918","1879-114X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Therapeutics","raw_type":"journal-article"},{"id":"pmid:31030995","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31030995","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical therapeutics","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W611976593","https://openalex.org/W1598844438","https://openalex.org/W2003788939","https://openalex.org/W2083105180","https://openalex.org/W2106793787","https://openalex.org/W2119542781","https://openalex.org/W2134443476","https://openalex.org/W2778606863","https://openalex.org/W2789912955","https://openalex.org/W2804406807","https://openalex.org/W2914392887"],"related_works":["https://openalex.org/W2752713307","https://openalex.org/W2778606863","https://openalex.org/W2804406807","https://openalex.org/W4295935779","https://openalex.org/W2789912955","https://openalex.org/W3010816592","https://openalex.org/W2896658653","https://openalex.org/W2158190550","https://openalex.org/W2981961965","https://openalex.org/W2799714015"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":6},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-05-03T00:00:00"}